ABCL (AbCellera Biologics) Total Liabilities: $369.03 Mil (As of Mar. 2026)

What is AbCellera Biologics Total Liabilities?

AbCellera Biologics ABCL +10.81% 59 Total Liabilities is $369.03 Mil as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review.

AbCellera Biologics's Total Liabilities for the quarter that ended in Mar. 2026 was $369.03 Mil.

AbCellera Biologics's quarterly Total Liabilities declined from Sep. 2025 ($391.95 Mil) to Dec. 2025 ($390.05 Mil) and declined from Dec. 2025 ($390.05 Mil) to Mar. 2026 ($369.03 Mil).

AbCellera Biologics's annual Total Liabilities declined from Dec. 2023 ($335.78 Mil) to Dec. 2024 ($304.47 Mil) but then increased from Dec. 2024 ($304.47 Mil) to Dec. 2025 ($390.05 Mil).

AbCellera Biologics Total Liabilities Related Terms

AbCellera Biologics Total Liabilities Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Total Liabilities Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

292.84

307.63

335.78

304.47

390.05

AbCellera Biologics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															321.23	394.99	391.95	390.05	369.03

59GF Score

AbCellera Biologics Inc ABCL

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AbCellera Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AbCellera Biologics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	64.307	+	(137.403	+	4.768
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	183.568	+	0	+	0)
	=	390.05

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	1356.95	-	966.904
	=	390.05

AbCellera Biologics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	47.294	+	(134.309	+	11.321
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	176.105	+	0	+	0)
	=	369.03

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	1307.112	-	938.083
	=	369.03

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $369.03 Mil mean?

AbCellera Biologics (ABCL) has a Total Liabilities of $369.03 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AbCellera Biologics and its competitors.

Is AbCellera Biologics' Total Liabilities too high?

AbCellera Biologics' current Total Liabilities is $369.03 Mil. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does AbCellera Biologics' Total Liabilities compare to SRPT and RAPP?

AbCellera Biologics' Total Liabilities of $369.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AbCellera Biologics and its competitors. AbCellera Biologics's current Total Liabilities is $369.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AbCellera Biologics stock overvalued right now?

Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Total Liabilities is $369.03 Mil. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Total Liabilities is $369.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

Total Liabilities: $369.03 Mil
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies SRPT RAPP RXRX STOK ADMA ZYME SION NRIX IOVA HRMY VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 8QQ:Germany

Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6

Website https://www.abcellera.com

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

59GF Score

Get the complete analysis for ABCL

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.38

Price

$5.62

GF Value

View ABCL Analysis

See Total Liabilities data for all stocks →